IMV Inc.

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Careers
    • Overview
    • Life at IMV
  • The DPX™ Platform
    • Overview
    • Scientific Publications & Posters
  • Clinical Pipeline
    • Overview
    • Maveropepimut-S
    • DPX-RSV
    • DPX-COVID-19
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • Email Alerts
    • Annual General and Special Shareholders Meeting
  • Investors
    • Overview
    • Press Releases
    • Events, Webcasts & Presentations
    • Financial Info
    • Stock Data
    • Filings
    • Governance
    • Contact Us
    • FAQ
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events, Webcasts & Presentations
    • Overview
    • Presentations
    • Scientific Publications & Posters
    • Email Alerts
  • Financial Info
    • Financial Results
    • Tax Info
    • Proxy Info
    • Stock Option Plan
    • Deferred Share Unit Plan
  • Stock Data
    • NASDAQ: IMV
    • TSX: IMV
    • Analyst Coverage
  • Filings
    • SEC Filings
    • SEDAR
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Contact Us
  • FAQ
Oct 21, 2014 8:05am EDT

Immunovaccine Demonstrates Protection Against Lethal Anthrax Challenge With Rapid Acting, Single Dose Vaccine

Oct 06, 2014 8:05am EDT

Immunovaccine to Provide Update on Ongoing Ebola Virus and Cancer Vaccine Programs at 13th Annual BIO Investor Forum

Oct 06, 2014 8:00am EDT

Immunovaccine Announces Changes to Stock Option Plan

Oct 01, 2014 8:05am EDT

Immunovaccine Announces Plans for Phase II Clinical Trial of DPX-Survivac in Patients with Recurrent Lymphoma

Sep 26, 2014 8:05am EDT

Immunovaccine Adds Broad Business Operations and Capital Raising Expertise to Board of Directors with New Appointments

Aug 25, 2014 10:30am EDT

Ebola Vaccine Using Immunovaccine's DepoVax Proves Highly Efficacious in Non-Human Primate Study

Aug 15, 2014 8:05am EDT

Immunovaccine Announces Financial Results for Quarter Ended June 30, 2014

Aug 12, 2014 8:05am EDT

Immunovaccine to Present at Ninth Annual Immunotherapies and Vaccines Summit (ImVacS) Conference

Jun 11, 2014 9:18am EDT

Immunovaccine Appoints Marc Mansour as Chief Executive Officer

Jun 02, 2014 8:05am EDT

Immunovaccine Reports Promising Clinical Activity for Novel T Cell Activating Immunotherapy DPX-Survivac at ASCO 2014

RSS
  • Prev
  • 1...
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • ...40
  • Next
  • Email Alerts
  • Contacts
  • RSS News Feed
IMV Inc.
About Us Careers The DPX™ Platform Clinical Pipeline News & Events Investors Contact
Twitter LinkedIn Youtube
© 2022 IMV Inc. All Rights Reserved.
Privacy Policy Terms of Use Sitemap